Optimization of enrichment conditions on TiO2 chromatography using glycerol as an additive reagent for effective phosphoproteomic analysis.
Metal oxide affinity chromatography (MOAC) represented by titanium dioxide (TiO2) chromatography has been used for phosphopeptide enrichment from cell lysate digests prior to mass spectrometry. For in-depth phosphoproteomic analysis, it is important for MOAC to achieve high phosphopeptide enrichment efficiency by optimizing purification conditions. However, there are some differences in phosphopeptide selectivity and specificity enriched by various TiO2 materials and procedures. Here, we report that binding/wash buffers containing polyhydric alcohols, such as glycerol, markedly improve phosphopeptide selectivity from complex peptide mixtures. In addition, the elution conditions combined with secondary amines, such as bis-Tris propane, made it possible to recover phosphopeptides with highly hydrophobic properties and/or longer peptide lengths. To assess the practical applicability of our improved method, we confirmed using PC3 prostate cancer cells. By combining the hydrophilic interaction chromatography (HILIC) with the optimized TiO2 enrichment method prior to LC-MS/MS analysis, over 8300 phosphorylation sites and 2600 phosphoproteins were identified. Additionally, some dephosphorylations of those were identified by treatment with dasatinib for a kinase inhibitor. These results indicate that our method is applicable to understanding the profiling of kinase inhibitors such as anticancer compounds, which will be useful for drug discovery and development.
Shionogi Pharmaceutical Research Center, Shionogi & Co. Ltd. , 3-1-1 Futaba-cho, Toyonaka-shi, Osaka 561-0825, Japan.
Isao
I
Fukuda
Yoshino
Y
Hirabayashi-Ishioka
Ikue
I
Sakikawa
Takeshi
T
Ota
Mari
M
Yokoyama
Takaoki
T
Uchiumi
Atsushi
A
Morita
D000595:Amino Acid Sequence; D045744:Cell Line, Tumor; D002846:Chromatography, Affinity; D000069439:Dasatinib; D055808:Drug Discovery; D005990:Glycerol / Q000737:chemistry*; D006801:Humans; D008297:Male; D008969:Molecular Sequence Data; D010748:Phosphopeptides / Q000032:analysis*; D010750:Phosphoproteins / Q000032:analysis*; D047428:Protein Kinase Inhibitors / Q000494:pharmacology; D059748:Proteolysis; D040901:Proteomics; D011743:Pyrimidines / Q000494:pharmacology; D013844:Thiazoles / Q000494:pharmacology; D014025:Titanium / Q000737:chemistry*; D014325:Tromethamine / Q000031:analogs & derivatives
D010748:Phosphopeptides; D010750:Phosphoproteins; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013844:Thiazoles; D014325:Tromethamine; C009495:titanium dioxide; C034249:1,3-bis(tris(hydroxymethyl)methylamino)propane; D014025:Titanium; D005990:Glycerol; D000069439:Dasatinib